China Economic Net, Beijing, December 5 - Fuxiang Pharmaceutical (300497SZ) shares closed at 1007 yuan, down 156%。
The company disclosed last night that the "2023 Annual Plan for Issuance of ** to Specific Objects by Simplified Procedure" stated that the issuance of ** to specific objects by simplified procedure is no more than 35 specific objects such as legal persons, natural persons or other qualified investors who meet the requirements of the ** regulatory authorities. The final issuance object will be determined by the board of directors of the company and the sponsor (lead underwriter) according to the authorization of the general meeting of shareholders according to the subscription situation. All issuers of the Offering were subscribed for in cash.
The pricing benchmark date of this offering is the first day of the issuance period, and the issuance ** shall not be less than 80% of the average price of the company in the 20 trading days before the pricing benchmark date. (The calculation formula is: 20 trading days before the pricing base date**average trading price = 20 trading days before the pricing base date**total trading volume** 20 trading days before the pricing base date** total trading volume).
The ** type of the issuance is domestically listed RMB ordinary shares (A shares), with a par value of RMB 1 per share00 yuan. The issuance will be listed and traded on the Shenzhen Stock Exchange. The type and quantity of this issuance are domestically listed RMB ordinary shares (A shares) issued to specific targets with a total financing amount of no more than RMB 300 million and no more than 20% of the net assets at the end of the most recent year, and the number of shares issued is determined according to the total amount of funds raised divided by the issuance **, and does not exceed 30% of the total share capital of the company before the issuance.
The total amount of funds raised in this offering shall not exceed (including) RMB30,000000,000 yuan, the net proceeds after deducting the issuance expenses will be used to invest in new projects with an annual output of 5,000 tons of carboxylic acid series products and replenish working capital.
As of the date of the announcement of the plan, the issuance object has not yet been determined;If there is a related party subscription of the shares issued by a related party constitutes a related party transaction, the company will review and disclose it in a timely manner in accordance with the relevant regulations.
As of September 30, 2023, Bao Jianhua, the controlling shareholder and actual controller of the issuer, directly held 1928% stake;Holding the company's shareholder Fuxiang Investment 5785% of the shares, forming a controlling relationship with Fuxiang Investment, Fuxiang Investment directly holds the company's 137% stake;Ke Dan, Bao Danhong, and Ke Xili are the persons acting in concert with Bao Jianhua and hold the company respectively. 12% and 0004% shares. Bao Jianhua's actual total voting rights in the company are 2142%。The number of the issuance is determined according to the total amount of funds raised divided by the issuance **, and does not exceed 30% of the total share capital before the issuance, and the final maximum number of issuance is subject to the number of registrations agreed by the China Securities Regulatory Commission. After this issuance, Bao Jianhua will still maintain the status of the largest shareholder, and will still be the controlling shareholder and actual controller of the company, and this issuance will not lead to a change in the control of the company. The implementation of the issuance plan will not lead to the company's equity distribution not meeting the listing conditions.
The company said that through this issuance, the company's future development strategy can be implemented and core competitiveness can be enhancedOptimize the company's capital structure and enhance the company's operational capabilities.
According to the "Special Report on the Deposit and Use of the Previous Raised Funds" disclosed by Fuxiang Pharmaceutical on the evening of December 3, the company publicly issued 4.2 million convertible corporate bonds on March 1, 2019, with a face value of 100 yuan each, and the total amount of funds raised was RMB 420,000,00000 yuan, deducting the issuance cost of 8,016,144After 42 yuan, the net amount of funds raised was 411,983,85558 yuan. The above raised funds have been verified by Lixin Certified Public Accountants (Special General Partnership) on March 8, 2019 Xinhuishi Bao Zi 2019 No. ZF10054 "Capital Verification Report on the Receipt of Subscribed Funds". In order to standardize the management and use of the company's raised funds, the company has carried out special account storage of the raised funds, and signed a tripartite supervision agreement with banks and sponsors on the raised funds.
In addition, with the approval of the Zheng Jian Xu Xu [2020] No. 3231 issued by the China Securities Regulatory Commission, the company issued 79,191,640 ordinary shares (A shares) to specific targets00 shares, par value 100 yuan, issue **1268 yuan shares, a total of 1,004,149,995 raisedRMB20, deducting RMB10,000,000 for sponsorship and underwriting issuance fees00 yuan, deducting other external expenses directly related to the issuance of equity** 2,785,93352 yuan, and the actual net amount of funds raised was 991,364,06167 yuan. The above-mentioned raised funds were in place on December 31, 2020, verified by Lixin Certified Public Accountants (Special General Partnership), and issued by it Xinhuishi Bao Zi [2021] No. ZF10008 Capital Verification Report, which has been deposited in the special account for raised funds. The company adopts a special account storage system for the raised funds, and has signed a tripartite supervision agreement with the sponsor institution and the opening bank where the raised funds are deposited.
On May 11, 2020, the company increased 6 shares for every 10 shares and paid a pre-tax dividend of 2 yuan, with an ex-dividend date of May 18, 2020 and a share record date of May 15, 2020On May 30, 2019, the company gave 2 shares for every 10 shares and paid a pre-tax dividend of 2 yuan, with an ex-dividend date of June 6, 2019 and an equity record date of June 5, 2019.
According to Fuxiang Pharmaceutical's third quarter report in 2023, in the third quarter of 2023, the company achieved operating income of 43.1 billion yuan, a year-on-year increase of 741%；Net profit attributable to shareholders of the listed company - 2196240,000 yuan, a year-on-year decrease of 383604%；Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -2240080,000 yuan, a year-on-year decrease of 76149%。
In the first three quarters of 2023, the company achieved operating income of 128.6 billion yuan, a year-on-year increase of 440%；Net profit attributable to shareholders of the listed company was -8163690,000 yuan, a year-on-year decrease of 27785%；Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -8296170,000 yuan, a year-on-year decrease of 32945%, net cash flow from operating activities was -1657010,000 yuan.
*: China Economic Net.